Ajanta Pharmaceuticals
Market cap ₹40,909 Cr
- P/E
- 32.41
- Day range
- ₹3,268.00 – ₹3,340.00
- 52-week range
- ₹2,446.80 – ₹3,796.00
- Volume
- 86,171
- Open
- ₹3,300.00
- Prev close
- ₹3,312.50
Latest results · Q2 FY27(consolidated)Revenue ₹1,794 Cr+32.5%Profit ₹388 Cr+49.2%Margin 21.6%YoY vs the same quarter last year
1 red flag to read up on
- medium
Promoter holding falling
63.47%, down 2.78 pts since 2025-09-30 · 30 Sept 2026
From NSE and BSE filings. A flag is a reason to read the filing, not a rating.
AJANTPHARM in NSE indices and F&O
Research profile
Composite 65 / 100Factor percentiles
Derived metrics
- Earn. yield
- 3.1%
- Graham no.
- ₹938.97
- vs Graham
- -71.3%
- ROE ÷ P/B
- 3.0%
- 12-1 mom.
- +31.6%
- Return / vol
- 1.17
- Magic Formula
- #106
- Piotroski
- 2/6
- FCF yield
- 0.4%
Appears in 14 scans
Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.
Peer comparison
All 68 in Pharma| Company | M-cap | P/E | P/B | ROE | ROCE | OPM | D/E | Sales YoY |
|---|---|---|---|---|---|---|---|---|
| Sun PharmaSUNPHARMA | ₹4.49 L Cr | 40.95 | 5.03 | 14.8% | 21.0% | 29.0% | 0.04 | +11.9% |
| Divi's LaboratoriesDIVISLAB | ₹2.93 L Cr | 87.19 | 16.88 | 16.2% | 22.0% | 43.0% | 0.00 | +35.4% |
| Torrent PharmaTORNTPHARM | ₹1.75 L Cr | 77.88 | 9.67 | 26.8% | 15.0% | 33.0% | 0.77 | +50.8% |
| Apollo HospitalsAPOLLOHOSP | ₹1.27 L Cr | 56.40 | 11.55 | 22.6% | 17.0% | 16.0% | 0.77 | +23.0% |
| Laurus LabsLAURUSLABS | ₹1.25 L Cr | 93.72 | 19.82 | 18.2% | 18.0% | 34.0% | 0.43 | +33.5% |
| Zydus LifesciencesZYDUSLIFE | ₹1.20 L Cr | 28.72 | 4.32 | 20.1% | 21.0% | 24.0% | 0.50 | +29.2% |
| Dr. Reddy's LabsDRREDDY | ₹1.17 L Cr | 41.63 | 2.97 | 11.6% | 13.0% | 20.0% | 0.19 | -1.5% |
| Ajanta PharmaceuticalsAJANTPHARM | ₹40,909 Cr | 32.41 | 8.44 | 25.4% | 35.0% | 31.0% | 0.03 | +32.5% |
| Sector median | ₹24,603 Cr | 43.68 | 5.46 | 15.1% | 17.0% | 24.0% | 0.17 | +22.7% |
Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.
Key metrics
- P/E (TTM)
- 32.4
- Price / Book
- 8.42
- ROE (FY26)
- 25.4%
- ROCE (latest year)
- 35%
- Dividend yield
- 0.98%
Moving averages (NSE)
- 20-day
- ₹3,340.93
- Price below
- 50-day
- ₹3,430.75
- Price below
- 200-day
- ₹3,200.35
- Price above
Charts & trends
From company filings. Amounts in ₹ crore.
Revenue, profit & margin - quarterly
₹ crore; a loss shows red. Operating margin below, same periods.
- Revenue
- Net profit
Operating margin
Who owns the company
% of equity by quarter, latest Sept 2026
- Promoter
- DII
- FII
- Public
- Government
Cash flows
Where cash came from and went, by fiscal year (₹ crore)
- Operating
- Investing
- Financing
- Free cash flow
Return on equity
Net profit over shareholders' equity, by fiscal year
Equity vs debt
Shareholders' equity against borrowings (₹ crore); the ratio below, same years.
- Equity
- Debt
Debt to equity
Dividends per share
₹ by fiscal year of the ex-date; the latest year runs to date. Not adjusted for the bonus of 22 Jun 2022: earlier bars are per pre-bonus share.
Financial statements
| Line item | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,105 | 1,054 | 1,145 | 1,187 | 1,146 | 1,170 | 1,303 | 1,354 | 1,375 | 1,422 | 1,626 | 1,794 |
| Expenses | 791 | 776 | 815 | 875 | 825 | 873 | 951 | 1,026 | 993 | 1,088 | 1,202 | 1,247 |
| Operating Profit | 314 | 278 | 330 | 311 | 321 | 297 | 351 | 328 | 382 | 333 | 424 | 548 |
| OPM % | 28% | 26% | 29% | 26% | 28% | 25% | 27% | 24% | 28% | 23% | 26% | 31% |
| Other Income | 14 | 36 | 26 | 19 | 30 | 18 | 26 | 59 | 25 | 61 | 71 | 37 |
| Interest | 2 | 2 | 1 | 6 | 8 | 6 | 5 | 3 | 5 | 2 | 3 | 2 |
| Depreciation | 34 | 34 | 34 | 34 | 36 | 40 | 41 | 43 | 44 | 45 | 44 | 48 |
| Profit before tax | 291 | 278 | 322 | 290 | 307 | 269 | 331 | 341 | 359 | 347 | 447 | 535 |
| Tax % | 28% | 27% | 24% | 25% | 24% | 16% | 23% | 24% | 24% | 23% | 25% | 27% |
| Net Profit | 210 | 203 | 246 | 216 | 233 | 225 | 255 | 260 | 274 | 267 | 334 | 388 |
| EPS in Rs | ₹16.39 | ₹15.82 | ₹19.68 | ₹17.33 | ₹18.64 | ₹18.03 | ₹20.44 | ₹20.83 | ₹21.91 | ₹21.35 | ₹26.75 | ₹31.06 |
From company filings, updated 19 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.
Working-capital cycle
+31 days since Mar 2021
-145 days since Mar 2021
-44 days since Mar 2021
-69 days since Mar 2021
-15 days since Mar 2021
Strengths, risks & growth
Ajanta Pharma is primarily engaged in development, manufacturing and marketing of speciality pharmaceutical quality finished dosages.(Source : 202003-01 Annual Report Page No:70).
Strengths
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 25.2%
- Company has been maintaining a healthy dividend payout of 50.1%
Risks
- Stock is trading at 8.42 times its book value
Compounded Sales Growth
- 10 Years
- +12%
- 5 Years
- +14%
- 3 Years
- +13%
- TTM
- +25%
Compounded Profit Growth
- 10 Years
- +10%
- 5 Years
- +12%
- 3 Years
- +24%
- TTM
- +30%
Stock Price CAGR
- 10 Years
- +11%
- 5 Years
- +18%
- 3 Years
- +18%
- 1 Year
- +30%
Return on Equity
- 10 Years
- +23%
- 5 Years
- +23%
- 3 Years
- +25%
- Last Year
- +27%
Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.
Shareholding pattern
| Holder | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 | Change |
|---|---|---|---|---|---|
| Promoter | 66.25% | 66.25% | 63.49% | 63.47% | -0.02 pp |
| FII | 7.97% | 8.26% | 7.68% | 7.62% | -0.06 pp |
| DII | 18.58% | 18.36% | 21.80% | 21.94% | +0.14 pp |
| Government | 0.01% | 0.01% | 0.00% | 0.00% | 0.00 pp |
| Public | 7.20% | 7.14% | 7.03% | 6.96% | -0.07 pp |
Filed with NSE for Sept 2026: promoters 63.47%, public 36.53%
Analysts & fund holdings
Who holds the shares, quarter by quarter
Mutual funds 17.95% (-0.15 pp)- Promoters63.5%
- Foreign institutions7.6%
- Mutual funds17.9%
- Insurance3.6%
- Other domestic institutions0.4%
- Retail5.6%
- Others1.4%
| Fund | % of company | % of fund | 3-month change |
|---|---|---|---|
| Nippon India Small Cap Fund | 1.40% | 0.76% | +0.03 pp |
| Kotak Flexi Cap Fund | 1.35% | 1.08% | +0.08 pp |
| UTI Flexi Cap Fund | 1.08% | 2.03% | +0.11 pp |
| Kotak Small Cap Fund | 0.97% | 2.13% | +0.03 pp |
| Kotak Large & Mid Cap Fund | 0.82% | 1.12% | +0.06 pp |
Scorecard
- Performance
- Avg
- Valuation
- High
- Growth
- Low
- Profitability
- High
- Entry point
- Good
- Red flags
- Low
Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.
Risk & trend
From 292 daily sessions to 18 Nov 2026.
Risk
- Volatility (1Y)
- 25.2%
- Downside volatility
- 22.4%
- Worst 5% of days
- 2.5%
- Average of that tail
- 3.0%
- Max drawdown (1Y)
- 13.2%
- Below its peak
- 12.0%
Against the market
- Beta vs Nifty 50
- 0.46
- Correlation
- 0.24
- Relative strength (3M)
- -15.8%
- ATR (14)
- 3.2%
Return
- Return 1M
- -1.7%
- Return 3M
- -12.0%
- Return 6M
- +1.9%
- Return 1Y
- +29.5%
- vs 200-day average
- +2.3%
Momentum
- RSI (14)
- 42.0
- MACD histogram
- -0.22
- Stochastic %K
- 5.9
- ADX (14)
- 11.0
- +DI / −DI
- 19.3 / 17.9
- Money flow index
- 45.5
Participation
- Delivery (20d avg)
- 55.0%
- vs its 60-day baseline
- +0.6 pts
- Volume vs 20-day
- -0.5σ
- Close vs day's VWAP
- -0.7%
- 52-week position
- 67 / 100
These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.
Financial quality
From consolidated statements to 30 Sept 2026.
Piotroski F-Score
2 of 6 tested
- Return on assets positive — passed
- Operating cash flow positive — not testableno cash flow statement for this period
- Return on assets improving — failed
- Cash flow exceeds profit — not testableneeds cash flow and profit against assets
- Debt to assets falling — failed
- Current ratio improving — failed
- No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
- Operating margin improving — passed
- Asset turnover improving — failed
- Free cash flow
- ₹164 Cr
- FCF yield
- 0.4%
- Cash conversion
- 0.50
- Accruals ratio
- 0.086
- Net debt
- ₹64 Cr
- Net debt / equity
- 0.01
- EV / sales
- 6.59
- Capex intensity
- 6.7%
- Revenue CAGR
- 32.9%
- Profit CAGR
- 43.7%
Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.
Insider trades
| Person | Type | Shares | Value | Disclosed |
|---|---|---|---|---|
SHAILESH R SINGH Other · Market Sale | Sell | 607 | ₹18.8 L | 13 Mar 2026 |
SHAILESH R SINGH Other · Market Sale | Sell | 750 | ₹20.3 L | 29 Dec 2025 |
SHAILESH R SINGH Other · Market Sale | Sell | 3,000 | ₹75.9 L | 13 Nov 2025 |
SHAILESH R SINGH Other · Market Sale | Sell | 2,000 | ₹51.3 L | 13 Nov 2025 |
Disclosures filed with NSE under SEBI (Prohibition of Insider Trading) Regulations. Pledges and releases are not trades and are not counted above.
Corporate actions
- dividend₹32.00
Interim Dividend - Rs 32 Per Share
5 Aug 2026ex-date - dividend₹28.00
Interim Dividend - Rs 28 Per Share
10 Nov 2025ex-date - dividend₹28.00
Interim Dividend - Rs 28 Per Share
6 Nov 2024ex-date - buybackNot available — not reported in this filing
Buy Back
30 May 2024ex-date - dividend₹26.00
Interim Dividend - Rs 26 Per Share
8 Feb 2024ex-date - dividend₹10.00
Interim Dividend - Rs 10 Per Share/Special Dividend - Rs 15 Per Share
4 Aug 2023ex-date - buybackNot available — not reported in this filing
Buy Back
24 Mar 2023ex-date - dividend₹7.00
Interim Dividend - Rs 7 Per Share
11 Nov 2022ex-date - bonusNot available — not reported in this filing
Bonus- 1:2
22 Jun 2022ex-date - buybackNot available — not reported in this filing
Buyback
13 Jan 2022ex-date - dividend₹9.50
Interim Dividend - Rs 9.50 Per Share
9 Nov 2021ex-date - buybackNot available — not reported in this filing
Buyback
12 Nov 2020ex-date - dividend₹9.50
Interim Dividend - Rs 9.50 Per Share
12 Nov 2020ex-date - otherNot available — not reported in this filing
Annual General Meeting
21 Jul 2020ex-date - dividend₹13.00
Interim Dividend - Rs 13 Per Share
15 Nov 2019ex-date - otherNot available — not reported in this filing
Annual General Meeting
9 Jul 2019ex-date - buybackNot available — not reported in this filing
Buy Back
11 Feb 2019ex-date - dividend₹9.00
Interim Dividend - Rs 9 Per Sh
9 Nov 2018ex-date - otherNot available — not reported in this filing
Annual General Meeting
26 Jun 2018ex-date - otherNot available — not reported in this filing
Annual General Meeting
23 Jun 2017ex-date
Company announcements
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for CTL Trusteeship Ltd
Pls find enclosed herewith Sustainability Report for FY 2026.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on September 28, 2026 for Aayush Agrawal, ....
Pls find enclosed herewith closure of trading window intimation
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on September 18, 2026 for Aayush Agrawal, ....
Pls find enclosed Intimation w.r.t Participation in Investor Conference.
Pls find enclosed newspaper publication for transfer of equity shares to IEPF.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 27, 2026 for Aayush Agrawal, trustee ....
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 19, 2026 for Ravi Agrawal, trustee ....
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 14, 2026 for Ravi Agrawal, trustee ....
Pls find enclosed Intimation w.r.t participation in Investor Conference
Pls find enclosed herewith Earning Call Transcript
Pls find enclosed newspaper publication of financial results for the quarter ended 30.06.2026.
Pls find enclosed Audio Recording of Earnings Call
Pls find enclosed ESOP Allotment
Filed with BSE (scrip 532331); the last 45 days. Documents open at bseindia.com.
Documents
Annual reports
Earnings calls
- Oct 2026Recording
- Aug 2026TranscriptSlidesRecording
- May 2026TranscriptRecording
- Jan 2026TranscriptSlidesRecording
- Nov 2025TranscriptSlidesRecording
- Jul 2025TranscriptSlides
Credit ratings
- Rating update · 14 Aug from care
- Rating update · 25 Aug 2025 from care
- Rating update · 29 Aug 2024 from care
- Rating update · 12 Sep 2023 from care
- Rating update · 12 Sep 2022 from care
- Rating update · 31 Aug 2021 from care
Documents open at BSE or the rating agency that issued them.
Sourced from the company's NSE XBRL filing dated 30 Oct 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.
Ajanta Pharmaceuticals: common questions
Answered from the figures on this page.